Placebo News and Research

RSS

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

7 May 2011

Neutralizing antibodies generated by immunization associated with protection against SIV infection

Using a monkey model of AIDS, scientists have identified a vaccine-generated immune-system response that correlates with protection against infection by the monkey version of HIV, called simian immunodeficiency virus (SIV). The researchers found that neutralizing antibodies generated by immunization were associated with protection against SIV infection.

6 May 2011

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration approved Afinitor tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.

6 May 2011

New drugs need to provide more data on how they compare with existing ones: Study

According to US researchers, data on drugs that could save money and help doctors make smarter treatment decisions are often unavailable at the time new medicines hit the market. They released a study this Tuesday in Journal of the American Medical Association which found nearly a third of new drug approvals from the Food and Drug Administration included no data on how well the medications compare with existing alternatives.

5 May 2011

Asthma ‘pill-a-day’ shows similar effectiveness as inhalers: Study

A new study has shown that a ‘once-a-day’ pill may be on par with an inhaler at combating asthma. This tablet, say researchers could revolutionize treatment for the condition, meaning patients are no longer reliant on inhalers, which many find difficult to use. Around 5.4 million Britons have asthma, including 1.1 million children.

5 May 2011

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

Pfizer Inc. announced that Revatio (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.

5 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2011.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

Columbia Laboratories net revenues increase 74% to $12.5 million

Columbia Laboratories, Inc. today reported financial results for the three-month period ended March 31, 2011.

5 May 2011

Clinical study: Celecoxib drug may treat breast cancer

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

5 May 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.

5 May 2011

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

Northwest Biotherapeutics today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal type of brain cancer.

4 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial

SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.

4 May 2011

Nile Therapeutics initiates cenderitide Phase I trial in heart failure

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced dosing of the first patient in a Phase I clinical trial investigating the use of subcutaneous cenderitide.

3 May 2011

Study: Dual medications do not hasten recovery from depression

Taking two medications for depression does not hasten recovery from the condition that affects 19 million Americans each year, researchers at UT Southwestern Medical Center have found in a national study.

3 May 2011

Placebo News and Research

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

Neutralizing antibodies generated by immunization associated with protection against SIV infection

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

New drugs need to provide more data on how they compare with existing ones: Study

Asthma ‘pill-a-day’ shows similar effectiveness as inhalers: Study

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

Acorda reports $0.7 million GAAP net loss for first quarter 2011

POZEN reports revenue of $4.5 million for first quarter 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

Columbia Laboratories net revenues increase 74% to $12.5 million

Clinical study: Celecoxib drug may treat breast cancer

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial

Nile Therapeutics initiates cenderitide Phase I trial in heart failure

Study: Dual medications do not hasten recovery from depression

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News